JP2023511376A5 - - Google Patents

Info

Publication number
JP2023511376A5
JP2023511376A5 JP2022544309A JP2022544309A JP2023511376A5 JP 2023511376 A5 JP2023511376 A5 JP 2023511376A5 JP 2022544309 A JP2022544309 A JP 2022544309A JP 2022544309 A JP2022544309 A JP 2022544309A JP 2023511376 A5 JP2023511376 A5 JP 2023511376A5
Authority
JP
Japan
Prior art keywords
domain
substitutions
heterodimer protein
protein according
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022544309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023511376A (ja
JP7710450B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/073347 external-priority patent/WO2021148006A1/en
Publication of JP2023511376A publication Critical patent/JP2023511376A/ja
Publication of JP2023511376A5 publication Critical patent/JP2023511376A5/ja
Priority to JP2025114854A priority Critical patent/JP2025160226A/ja
Application granted granted Critical
Publication of JP7710450B2 publication Critical patent/JP7710450B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022544309A 2020-01-23 2021-01-22 Fc変異を有するヘテロダイマータンパク質 Active JP7710450B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025114854A JP2025160226A (ja) 2020-01-23 2025-07-08 Fc変異を有するヘテロダイマータンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020073960 2020-01-23
CNPCT/CN2020/073960 2020-01-23
PCT/CN2021/073347 WO2021148006A1 (en) 2020-01-23 2021-01-22 Heterodimeric proteins with fc mutations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025114854A Division JP2025160226A (ja) 2020-01-23 2025-07-08 Fc変異を有するヘテロダイマータンパク質

Publications (3)

Publication Number Publication Date
JP2023511376A JP2023511376A (ja) 2023-03-17
JP2023511376A5 true JP2023511376A5 (cg-RX-API-DMAC7.html) 2025-04-21
JP7710450B2 JP7710450B2 (ja) 2025-07-18

Family

ID=76992067

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022544309A Active JP7710450B2 (ja) 2020-01-23 2021-01-22 Fc変異を有するヘテロダイマータンパク質
JP2025114854A Pending JP2025160226A (ja) 2020-01-23 2025-07-08 Fc変異を有するヘテロダイマータンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025114854A Pending JP2025160226A (ja) 2020-01-23 2025-07-08 Fc変異を有するヘテロダイマータンパク質

Country Status (12)

Country Link
US (1) US20230124669A1 (cg-RX-API-DMAC7.html)
EP (1) EP4093778A4 (cg-RX-API-DMAC7.html)
JP (2) JP7710450B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220145833A (cg-RX-API-DMAC7.html)
CN (1) CN115279796A (cg-RX-API-DMAC7.html)
AU (1) AU2021210482A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022014574A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165045A1 (cg-RX-API-DMAC7.html)
IL (1) IL294878A (cg-RX-API-DMAC7.html)
MX (1) MX2022009101A (cg-RX-API-DMAC7.html)
TW (1) TWI920054B (cg-RX-API-DMAC7.html)
WO (1) WO2021148006A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549157A (ja) * 2020-11-10 2023-11-22 リビジェン バイオファーマ ホールディングス リミテッド 抗cd137結合分子を含む二重特異性抗体
WO2022170619A1 (en) * 2021-02-11 2022-08-18 Adagene Pte. Ltd. Anti-cd3 antibodies and methods of use thereof
CN118339188A (zh) 2021-09-21 2024-07-12 齐鲁普吉湾生物治疗公司 用于制备融合蛋白和双特异性抗体的异二聚体Fc
EP4496816A1 (en) * 2022-03-23 2025-01-29 CytomX Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
WO2023193239A1 (en) 2022-04-08 2023-10-12 Peter Peizhi Luo Anti-cd28 antibodies and methods of use thereof
CN116724057A (zh) * 2022-11-28 2023-09-08 浙江时迈药业有限公司 蛋白酶可切割的重组双特异性抗体和组合物及其用途
JP2026524012A (ja) * 2023-07-10 2026-07-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性pd-l1×4-1bb抗体およびそれらの使用方法
KR20260115642A (ko) * 2023-11-20 2026-07-24 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 재조합 반응을 통해 이종다량체를 제조하는 방법
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201808537T4 (tr) * 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
US8054928B2 (en) * 2005-11-14 2011-11-08 Ati Technologies, Inc. Programmable preamble system and method
EP3543256A1 (en) * 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
US9493578B2 (en) * 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US20130089554A1 (en) * 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
IL299365A (en) * 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
IN2014CN03887A (cg-RX-API-DMAC7.html) * 2011-10-27 2015-10-16 Genmab As
WO2013118722A1 (ja) * 2012-02-06 2013-08-15 トヨタ自動車株式会社 硫化物固体電解質材料、電池および硫化物固体電解質材料の製造方法
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EP3587448B1 (en) * 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
AP2016009222A0 (en) * 2013-11-04 2016-05-31 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
US20160176969A1 (en) * 2014-11-26 2016-06-23 Xencor, Inc. Heterodimeric antibodies including binding to cd8
WO2016087416A1 (en) * 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
WO2016152136A1 (ja) * 2015-03-20 2016-09-29 日本電気株式会社 プラガブル光モジュール、光通信システム及びプラガブル光モジュールの制御方法
CN106883297B (zh) * 2015-12-16 2019-12-13 苏州康宁杰瑞生物科技有限公司 基于ch3结构域的异二聚体分子、其制备方法及用途
RU2745648C2 (ru) * 2016-07-19 2021-03-30 Ибентрус, Инк. Биспецифические белки и способы их получения
WO2019014912A1 (zh) * 2017-07-21 2019-01-24 赵磊 一种异二聚体蛋白及其制备方法
KR20260039804A (ko) * 2017-12-21 2026-03-20 아뮤닉스 파마슈티컬스, 인크. 유리 세그먼트 및 이것을 포함하는 결합 조성물
WO2019148445A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
TWI798601B (zh) * 2020-11-27 2023-04-11 晶睿通訊股份有限公司 地面起伏偵測方法及其監控攝影機
JP7295438B2 (ja) * 2020-11-30 2023-06-21 日亜化学工業株式会社 面状光源
WO2022170619A1 (en) * 2021-02-11 2022-08-18 Adagene Pte. Ltd. Anti-cd3 antibodies and methods of use thereof
WO2023193239A1 (en) * 2022-04-08 2023-10-12 Peter Peizhi Luo Anti-cd28 antibodies and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2025160226A5 (cg-RX-API-DMAC7.html)
EP2414391B1 (en) Multispecific antibodies comprising full length antibodies and single chain fab fragments
TWI359027B (en) Bivalent, bispecific antibodies
JP2022551969A5 (cg-RX-API-DMAC7.html)
US20220002398A1 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
JP2019533441A5 (cg-RX-API-DMAC7.html)
JP2024508671A5 (cg-RX-API-DMAC7.html)
AU2015329965A1 (en) Bispecific antibodies against CD3epsilon and ROR1
JP2023516004A5 (cg-RX-API-DMAC7.html)
JP2023548529A5 (cg-RX-API-DMAC7.html)
JP2021507698A5 (cg-RX-API-DMAC7.html)
JP2026027248A (ja) 抗原結合分子およびその使用
JP2023516941A5 (cg-RX-API-DMAC7.html)
JP2025508317A5 (cg-RX-API-DMAC7.html)
WO2018237341A1 (en) A TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT FOR CANCER THERAPY
WO2025041097A1 (en) Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof
JP2024502095A (ja) 二重または多重特異性抗体{Bi or Multi-Specific Antibody}
JP2021531757A5 (cg-RX-API-DMAC7.html)
JP2025511000A5 (cg-RX-API-DMAC7.html)
WO2025024780A1 (en) Antibodies that bind gamma-delta t cell receptors for the treatment of cancer
WO2025255480A1 (en) Tetravalent multispecific binding molecules and methods of use thereof
RU2026104696A (ru) Антитела, связывающиеся с cd3
NZ807450A (en) Antibodies binding to gprc5d
JP2022028645A5 (cg-RX-API-DMAC7.html)
RU2025130619A (ru) Биспецифические агонистические антитела к рецептору i типа, подобному рецептору активина а (alk1)